Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1297908rdf:typepubmed:Citationlld:pubmed
pubmed-article:1297908lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:1297908lifeskim:mentionsumls-concept:C0005586lld:lifeskim
pubmed-article:1297908lifeskim:mentionsumls-concept:C0016365lld:lifeskim
pubmed-article:1297908pubmed:issue4lld:pubmed
pubmed-article:1297908pubmed:dateCreated1993-5-5lld:pubmed
pubmed-article:1297908pubmed:abstractTextSixty patients (39 females and 21 males) aged between 20 and 65 (average 48.5) with bipolar disorder in the depressive phase, according to the DSM III-R diagnostic criteria, were treated with fluoxetine (20-60 mg/die) for 8 weeks. Evaluation of therapeutical efficacy was performed at 0 time and after 14, 28, 42, and 56 days, using the following psychometric tests; HAM-D, SCL-90, CGI. At the end of treatment 42 patients (70%) showed a reduction of the HAM-D score over 50%. Clinical results suggest that fluoxetine is affective in bipolar disorder. Tolerability was judged good and very good in 76% of patients. Side effects were very mild and in any case of rapid regression.lld:pubmed
pubmed-article:1297908pubmed:languageitalld:pubmed
pubmed-article:1297908pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1297908pubmed:citationSubsetIMlld:pubmed
pubmed-article:1297908pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1297908pubmed:statusMEDLINElld:pubmed
pubmed-article:1297908pubmed:issn0374-9320lld:pubmed
pubmed-article:1297908pubmed:authorpubmed-author:FilippiGGlld:pubmed
pubmed-article:1297908pubmed:authorpubmed-author:FilippiVVlld:pubmed
pubmed-article:1297908pubmed:authorpubmed-author:PaolettiCClld:pubmed
pubmed-article:1297908pubmed:authorpubmed-author:MarcheseGGlld:pubmed
pubmed-article:1297908pubmed:authorpubmed-author:ColonnaC VCVlld:pubmed
pubmed-article:1297908pubmed:authorpubmed-author:AmbrosioL ALAlld:pubmed
pubmed-article:1297908pubmed:authorpubmed-author:BarreseEElld:pubmed
pubmed-article:1297908pubmed:authorpubmed-author:BuccominoDDlld:pubmed
pubmed-article:1297908pubmed:issnTypePrintlld:pubmed
pubmed-article:1297908pubmed:volume33lld:pubmed
pubmed-article:1297908pubmed:ownerNLMlld:pubmed
pubmed-article:1297908pubmed:authorsCompleteYlld:pubmed
pubmed-article:1297908pubmed:pagination305-12lld:pubmed
pubmed-article:1297908pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1297908pubmed:meshHeadingpubmed-meshheading:1297908-...lld:pubmed
pubmed-article:1297908pubmed:meshHeadingpubmed-meshheading:1297908-...lld:pubmed
pubmed-article:1297908pubmed:meshHeadingpubmed-meshheading:1297908-...lld:pubmed
pubmed-article:1297908pubmed:meshHeadingpubmed-meshheading:1297908-...lld:pubmed
pubmed-article:1297908pubmed:meshHeadingpubmed-meshheading:1297908-...lld:pubmed
pubmed-article:1297908pubmed:meshHeadingpubmed-meshheading:1297908-...lld:pubmed
pubmed-article:1297908pubmed:meshHeadingpubmed-meshheading:1297908-...lld:pubmed
pubmed-article:1297908pubmed:meshHeadingpubmed-meshheading:1297908-...lld:pubmed
pubmed-article:1297908pubmed:meshHeadingpubmed-meshheading:1297908-...lld:pubmed
pubmed-article:1297908pubmed:meshHeadingpubmed-meshheading:1297908-...lld:pubmed
pubmed-article:1297908pubmed:meshHeadingpubmed-meshheading:1297908-...lld:pubmed
pubmed-article:1297908pubmed:meshHeadingpubmed-meshheading:1297908-...lld:pubmed
pubmed-article:1297908pubmed:articleTitle[Bipolar disorder: clinical trials with fluoxetine].lld:pubmed
pubmed-article:1297908pubmed:affiliationServizio di Psichiatria, Ospedale Civile Dell'Annunziata, Cosenza.lld:pubmed
pubmed-article:1297908pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1297908pubmed:publicationTypeEnglish Abstractlld:pubmed